KEARNEY
11.5.2023 10:40:25 CEST | Business Wire | Press release
Leading global consultancy partnership Kearney has today released new data showing revenue predictions and sentiment from senior telecommunications and consumer goods lead around the metaverse. The report also reveals that many senior leaders are still unsure what form this will take and how this will affect their businesses’ bottom lines.
The Pragmatic Leader’s Guide to the Metaverse reveals that a quarter of European consumer goods and telco leaders (25%) expect to see the metaverse account for revenues of between 5-20% by 2025, rising to more than half (52%) who expect this revenue by 2030. However, exactly how to monetise these emerging concepts remains unclear, constituting a real problem for many leaders, with 84% of telecom leaders and 64% of consumer goods leaders agreeing that companies will need to expand into new markets and channels to ensure relevance in the space.
At the higher end, almost one in 10 (9%) leaders in Europe expect between 20-50% of revenue to originate from the metaverse by 2030.
The Guide draws on qualitative analysis, leveraging insights from 167 senior telecoms and consumer goods decision-makers in companies with 1,000 to 50,000+ employees across Asia Pacific, North America and Europe.
Compared to Europe, only 10% of respondents in North America predicted that between 5-20% of revenue would stem from the metaverse by 2025. This figure then rises to 45% of respondents predicting this level of revenue by 2030.
Overall, 56% of consumer goods leaders and 59% of telco leaders in Europe see the metaverse as having a positive impact on their industry. However, one in four (24%) telco leaders were ‘very’ positive about the metaverse’s impact compared to only 3% of consumer goods professionals, showing that sentiment is still highest in the technology and communications space.
One of the biggest risks leaders associated with the metaverse was cybersecurity, with 57% of telco respondents and 63% of consumer goods European respondents citing this as a high impact risk to the metaverse. Interestingly, regulatory risk was also considered ‘high impact’ by 43% of telco respondents and 27% of consumer goods respondents.
Jesper Larsson, Partner at Kearney, comments:
“Global leaders clearly see the metaverse as a true avenue of growth over the next five to ten years, with some predictions suggesting significant levels of revenue could originate in this virtual marketplace. The key challenge, however, will be how to monetise the platform as a revenue stream.”
“Technologies enabling and supporting the use of the metaverse, such as 5G, could offer potential to overcome this monetisation challenge. Such technologies would support an increased flow of data and satisfy demand, building out the capability of this platform even as they make it more profitable. Indeed, the metaverse could be the very use case that 5G has been waiting on, to realise its true potential.”
Eric Gervet, Partner at Kearney, adds:
Where once we had been seeing positive global sentiment towards the use of the metaverse as a platform for growth and revenue, inflation and global economic slowdown have put tension on the Tech sector, which requires companies to make trade-offs and pace investments. Doubling down on AI and optimizing EBITDA has become a short-term priority versus longer term investments, at least for the very short term.”
“Companies that act now to develop a strategy for how the growth of the metaverse could impact their model will have a significant advantage over the competition in deciding which technologies, partnerships and investments will be necessary to access this revenue stream.”
ENDS
Notes to Editors
Methodology
In light of the hype surrounding the metaverse, our primary research was designed to provide a comprehensive and nuanced understanding of its potential impact on businesses and the overall readiness for the metaverse. We surveyed 167 industry leaders from Asia Pacific, North America, and Europe who hold influential positions as business executives in the telecom or consumer goods sectors. Participants were required to be currently employed at companies with a minimum of 1,000 employees and hold a position within three degrees of separation from the CEO.
About Kearney
Kearney is a leading global management consulting firm. For nearly 100 years, we have been the trusted advisor to C-suites, government bodies, and nonprofit organizations. Our people make us who we are. Driven to be the difference between a big idea and making it happen, we help our clients break through. www.kearney.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230509005937/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
